Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.

Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee.

Eur J Cancer. 2014 Mar;50(4):746-52. doi: 10.1016/j.ejca.2013.11.029. Epub 2013 Dec 11.

PMID:
24332573
2.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S.

BJU Int. 2011 Oct;108(8):1279-83. doi: 10.1111/j.1464-410X.2010.09990.x. Epub 2011 Jan 18.

3.

Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.

Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.

BJU Int. 2016 Jan;117(1):110-7. doi: 10.1111/bju.12940. Epub 2015 Jun 2.

4.

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

Poprach A, Bortlicek Z, Melichar B, Lakomy R, Svoboda M, Kiss I, Zemanova M, Fiala O, Kubackova K, Coufal O, Pavlik T, Dusek L, Vyzula R, Buchler T.

Eur J Cancer. 2015 Mar;51(4):507-13. doi: 10.1016/j.ejca.2014.12.010. Epub 2015 Jan 7.

PMID:
25577735
5.

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

Sternberg CN, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C.

Oncology. 2015;88(5):273-80. doi: 10.1159/000369256. Epub 2015 Jan 15.

PMID:
25592399
6.
7.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R.

Br J Cancer. 2015 Jun 30;113(1):12-9. doi: 10.1038/bjc.2015.196. Epub 2015 Jun 18.

8.

Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.

Shi HZ, Tian J, Chen X, Wang D, Li CL.

Clin Genitourin Cancer. 2017 Feb;15(1):139-144. doi: 10.1016/j.clgc.2016.05.007. Epub 2016 May 27.

PMID:
27338518
9.

Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.

Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B.

Ann Oncol. 2010 Aug;21(8):1618-22. doi: 10.1093/annonc/mdp603. Epub 2010 Jan 20.

PMID:
20089567
10.

Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.

Patel KB, Panchal HP, Karanwal AB, Parekh BB, Shah S, Prasad S.

Indian J Cancer. 2016 Jan-Mar;53(1):118-22. doi: 10.4103/0019-509X.180844.

11.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.

Cancer. 2012 Mar 1;118(5):1252-9. doi: 10.1002/cncr.26440. Epub 2011 Sep 6.

12.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group.

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

PMID:
22700990
13.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.

J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3.

PMID:
19652072
14.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E.

J Urol. 2014 Mar;191(3):611-8. doi: 10.1016/j.juro.2013.08.090. Epub 2013 Sep 7.

15.
16.

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.

Oncol Rep. 2010 Aug;24(2):507-10.

PMID:
20596640
17.

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.

Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S, Lee SY.

Jpn J Clin Oncol. 2015 Jun;45(6):576-83. doi: 10.1093/jjco/hyv045. Epub 2015 Apr 27.

18.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

19.

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.

Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI.

Eur J Cancer. 2014 Apr;50(6):1084-9. doi: 10.1016/j.ejca.2014.01.025. Epub 2014 Feb 19.

PMID:
24559686
20.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group.

Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Erratum in: Ann Oncol. 2016 Feb;27(2):366.

PMID:
26216384

Supplemental Content

Support Center